Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Blue Sky MD vs Kin Meds

Blue Sky MD
Graded #170

Lower grade

vs+5.400000000000006
Kin Meds
Graded #75

Higher grade

The verdict

Kin Meds takes it — 72.9/100 to 67.5/100.

Kin Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Kin Meds is a LegitScript-verified telehealth platform offering both compounded GLP-1s (semaglutide from $199/mo, tirzepatide from $249/mo) and brand-name FDA-approved options including Wegovy injection and…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueKin Meds +10
64
74
Dose & formulationKin Meds +29
64
93
Clinical oversightBlue Sky MD +13
87
74
Labs & monitoringBlue Sky MD +9
62
53
FulfillmentKin Meds +9
63
72
Contract termsEven
55
55
Blue Sky MD · left barKin Meds · right bar

The numbers

MetricBlue Sky MDKin Meds
WeighScore67.5/10072.9/100
GradeCC
Scorecard rank#170#75
Semaglutide$160/mo (starting dose, compounded)$149/mo (brand Wegovy)
Tirzepatide$240/mo (starting dose, compounded)$149/mo (brand Zepbound)
Coverage1 statesCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
Blue Sky MD

Graded #170 · C

Strengths

  • LegitScript certified and physician-led since 2008; one of the most established GLP-1 practices in the Southeast
  • Compounded semaglutide from $40/week (~$160/month) and tirzepatide from $60/week (~$240/month) — well below brand-name cost
  • Comprehensive program includes 1-on-1 wellness coaching, nutrition plans, hormone analysis, and a proprietary mobile app
  • Medication shipped directly to patients’ homes within 3–5 business days; telehealth visits available
  • Insurance accepted in many cases; affordable self-pay options for uninsured patients

Where it loses points

  • Geographic reach unclear — physical clinics in NC only; telehealth states beyond NC unconfirmed despite 'from virtually anywhere' claim
  • Pricing quoted per-week ($40 sema / $60 tirz) rather than per-month; higher-dose pricing not disclosed
  • Must enroll in full medical weight-loss program to access GLP-1 medications — medication-only Rx not offered
  • No explicit lab testing protocol published; online FAQ does not confirm labs are included
  • Small regional provider vs. national platforms; limited provider footprint outside North Carolina
Kin Meds

Graded #75 · C

Strengths

  • Publicly lists $199/mo compounded semaglutide and $249/mo compounded tirzepatide
  • Brand-name options too — Wegovy injection and pill, Zepbound, Foundayo from $149/mo entry pricing
  • LegitScript verified
  • Clearly identifies itself as the intake platform and a licensed third-party pharmacy as the dispenser
  • Broad longevity menu (Sermorelin, NAD+, Glutathione) plus TRT, hair, skin, and sexual health

Where it loses points

  • Legal entity name and state of incorporation not publicly disclosed
  • The third-party pharmacy partner isn't named, and Kin Meds isn't itself a licensed pharmacy
  • Per-state availability not listed
  • $149/mo brand pricing is the insured entry tier — cash-pay patients should expect higher real costs
  • Lab work and dose-titration support not clearly described

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard